ZIA CP005782 - 10070 (ZIA) | |||
---|---|---|---|
Title | HALT-C Study | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | O'Brien, Thomas | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $87,770 | Project Dates | 03/24/2004 - 00/00/0000 |
Fiscal Year | 2014 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) Interferon (5.0%) |
Liver Cancer (100.0%) | ||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Chemoprevention |
|||
Abstract | |||
The HALT-C trial was designed to evaluate the safety and efficacy of long-term PEG-interferon-?2a for treatment of chronic hepatitis C in patients who did not respond to previous interferon therapy and who have evidence of hepatic fibrosis by biopsy. I am collaborating with the HALT-C investigators to examine potential genetic predictors of response to treatment and fibrosis among HALT-C participants. |